



**7<sup>TH</sup> International Symposium on**  
**MULTIPLE RISK FACTORS IN CARDIOVASCULAR DISEASES**  
**Prevention and Intervention - Health Economics**  
**Venice (Lido), Italy - October 22-25, 2008**

**Co-chairs:**  
**A.M. Gotto, Jr. (New York, NY, USA)**  
**S.M. Grundy (Dallas, TX, USA)**  
**R. Paoletti (Milan, Italy)**

## SCOPE OF SYMPOSIUM

Multiple risk factors management is a critical area in cardiovascular prevention and therapy. The integrated view of this series of International Symposia on Multiple Risk Factors in CVD fits with the new approaches now prevailing which include combined control of lipid disorders, hypertension, thrombosis, diabetes, and the increasing use of polytherapy to reduce global cardiovascular risk. The meeting will provide also practical answers to the health care professionals who are often confronted with selecting either a single risk factor for treatment or treating several risk factors simultaneously and with which priority. The concept of "global patient" and of "personalized medicine" will be presented and discussed and much attention will also be devoted to health economic issues. The meeting also encompasses educational sessions for the specific needs of GPs.

## SCIENTIFIC PROGRAM *(Preliminary Outline)*

MORNING SCIENTIFIC SESSIONS	MAIN AREAS	TOPICS
<p><i>Morning Plenary</i>  <b><u>MULTIPLE RISK ASSESSMENT</u></b></p>	What has changed?	<ul style="list-style-type: none"> <li>- From the single risk factor to the multiple risk concept</li> <li>- Type of patients and how to treat him/her</li> <li>- Selection of patients</li> <li>- Effectiveness of risk factor treatment</li> <li>- How to estimate risk?</li> <li>- Pre-clinical organ damage</li> <li>- Harmonization among guidelines</li> </ul>
	Conventional and non conventional risk factors	<ul style="list-style-type: none"> <li>- Multiple Risk Factors after the INTERHEART Study: <i>Abnormal Lipids, Tobacco Use, Hypertension, Diabetes, Abdominal Obesity, Psychosocial Factors, Consumption of Fruits, Vegetables, and Alcohol, and Regular Physical Activity</i></li> <li>- New approaches on gender, ethnicity, age, familiarity, scholary, social deprivation, stress, air pollution, and indoor air pollution</li> <li>- Pathological risk factors</li> <li>- Iatrogenic risk factors</li> </ul>
	Non pharmacological approach	<ul style="list-style-type: none"> <li>- Lifestyle changes: smoking, alcohol, salt intake, sedentarity, malnutrition, drug addiction, stress management, sensibilization on risk factors, psychological wellness</li> </ul>
	Non pharmacological intervention	<ul style="list-style-type: none"> <li>- Dietary approaches to body weight, body size, body biochemistry</li> <li>- Exercise personalization</li> <li>- Body structure and correlates in the assessment of risk</li> <li>- Nutraceuticals</li> <li>- Diet, exercise and nutraceuticals: combination</li> </ul>
<p><i>Morning Plenary</i>  <b><u>CLINICAL ASSESSMENT OF MULTIPLE RISKS</u></b></p>	Cardiometabolism	<ul style="list-style-type: none"> <li>- Diabetes vs Hypertension vs Hypertriglyceridemia vs Obesity: a single disease or a single treatment?</li> <li>- Hypertension, Dyslipidemia, Diabetes, Inflammation, Obesity, Thrombosis: prevalence, treatment, different type of patients</li> <li>- Metabolic syndrome and cardiometabolic risk</li> </ul>
	Heart, stroke, thrombosis, and kidney disease	<ul style="list-style-type: none"> <li>- Early stage cardiac disease</li> <li>- Renal disease</li> <li>- Hypertension, microalbuminuria, IMT</li> <li>- Multiple organ failure</li> </ul>
	Heart and liver	<ul style="list-style-type: none"> <li>- Liver steatosis</li> <li>- Nonalcoholic steatohepatitis</li> <li>- Hepatic drug metabolism</li> <li>- Liver and lipid metabolism</li> </ul>
	Immune disease	<ul style="list-style-type: none"> <li>- Inflammation</li> <li>- Rheumatic diseases</li> <li>- HIV</li> <li>- SLE</li> </ul>

<b>Morning Plenary</b> <b><u>INTERVENTION</u></b> <b><u>AND PREVENTION</u></b> <b><u>OF MULTIPLE RISKS</u></b>	Critical issues in pharmacological intervention	<ul style="list-style-type: none"> <li>- Hypercholesterolemia</li> <li>- Hypertriglyceridemia</li> <li>- Hypertension</li> <li>- Cardiometabolism</li> <li>- Diabetes</li> <li>- Thrombosis</li> </ul>
	Prolonged therapy, compliance, safety	<ul style="list-style-type: none"> <li>- Multiple pharmacy</li> <li>- Efficacy</li> <li>- Side effects</li> <li>- Drug interaction</li> </ul>
	Combination therapy	<ul style="list-style-type: none"> <li>- Multiple pharmacy</li> <li>- Efficacy</li> <li>- Side effects</li> <li>- Drug interaction</li> </ul>
	New drugs and new clinical trials	<ul style="list-style-type: none"> <li>- New resins</li> <li>- Cholesterol absorption inhibitors</li> <li>- siRNA</li> <li>- Peptides</li> </ul>
<b>Morning Plenary</b> <b><u>PRACTICAL APPLICATION</u></b> <b><u>OF MULTIPLE RISK</u></b> <b><u>APPROACH IN</u></b> <b><u>STANDARD CARE</u></b>	Health Economics	<ul style="list-style-type: none"> <li>- Pharmacoconomy</li> <li>- Pharmacoutilsation</li> <li>- Pharmacovigilance</li> </ul>
	Round table: clinical application to the standard care	
<b>AFTERNOON</b> <b>SCIENTIFIC</b> <b>SESSIONS</b>	<b>Parallel</b> <b>Workshops</b>	On specific Topics (in depth discussions, methodology, practical applications, etc)



## INTERNATIONAL ADVISORY BOARD

*(Preliminary List of Invited Members)*

**M. Abbracchio** (Italy) - **D. Ardissino** (Italy) - **C.M. Ballantyne** (USA) - **P.J. Barter** (Australia) - **F. Bernini** (Italy) - **D.J. Betteridge** (UK) - **R. Bhattacharjee** (UK) - **H.B. Brewer, Jr.** (USA) - **W.V. Brown** (USA) - **L. Calabresi** (Italy) - **G. Calvo Rojas** (Spain) - **M.F. Camargo Maranhao** (Brazil) - **R. Carmena** (Spain) - **A.L. Catapano** (Italy) - **M.J. Chapman** (France) - **M. Chiariello** (Italy) - **A. Corsini** (Italy) - **F. Crea** (Italy) - **G. Crepaldi** (Italy) - **M. Davidson** (USA) - **J. Davignon** (Canada) - **P.P. De Feo** (Italy) - **S. Del Prato** (Italy) - **J.-P. Desprès** (Canada) - **R. Dietz** (Germany) - **G. Di Minno** (Italy) - **G. Di Pasquale** (Italy) - **R. Eckel** (USA) - **S. Fargion** (Italy) - **F. Fedele** (Italy) - **R. Fellin** (Italy) - **R. Ferrari** (Italy) - **C. Fiorentini** (Italy) - **G. Franceschini** (Italy) - **F. Franconi** (Italy) - **J.-C. Fruchart** (France) - **V. Fuster** (USA) - **C. Galli** (Italy) - **S. Giampaoli** (Italy) - **H. Ginsberg** (USA) - **D. Good** (UK) - **D. Greco** (Italy) - **H. Greten** (Germany) - **S.M. Grundy** (USA) - **S. Gupta** (India) - **A. Hamsten** (Sweden) - **B. Jonsson** (Sweden) - **M.B. Katan** (The Netherlands) - **T. Kita** (Japan) - **U. Landmesser** (Germany) - **A. Lanzavecchia** (Switzerland) - **J.C. LaRosa** (USA) - **C. La Vecchia** (Italy) - **E. Leitersdorf** (Israel) - **P. Libby** (USA) - **F. Locatelli** (Italy) - **T.F. Lüscher** (Switzerland) - **A. Maggi** (Italy) - **B. Maisch** (Germany) - **G. Mancia** (Italy) - **M. Mancini** (Italy) - **E. Mannarino** (Italy) - **J.F. Martin** (UK) - **A. Maseri** (Italy) - **Y. Matsuzawa** (Japan) - **A. McGuire** (UK) - **M.G. Modena** (Italy) - **M. Naruszewicz** (Poland) - **S.E. Nissen** (USA) - **A. Notarbartolo** (Italy) - **S. Novo** (Italy) - **A.G. Olsson** (Sweden) - **C.J. Packard** (UK) - **J.R. Patsch** (Austria) - **T.R. Pedersen** (Norway) - **A. Peracino** (Italy) - **J. Perk** (Sweden) - **M. Plebani** (Italy) - **A. Poli** (Italy) - **P. Poole-Wilson** (UK) - **K.S. Reddy** (India) - **G. Remuzzi** (Italy) - **S. Sadikot** (India) - **S. Sans** (Spain) - **E.J. Schaefer** (USA) - **K. Schenck-Gustafsson** (Sweden) - **C.R. Sirtori** (Italy) - **L. Sjöstrom** (Sweden) - **P. Sleight** (UK) - **J. Sobesky** (Germany) - **V. Stangl** (Germany) - **Y. Stein** (Israel) - **J.C. Tardif** (Canada) - **M.R. Taskinen** (Finland) - **L. Tavazzi** (Italy) - **L. Tokgözoğlu** (Turkey) - **E. Tremoli** (Italy) - **G. Utermann** (Austria) - **S. Vella** (Italy) - **M. Venegoni** (Italy) - **M. Volpe** (Italy) - **N.K. Wenger** (USA) - **S.L.C. Woo** (USA) - **D. Wood** (UK) - **A. Wu** (USA) - **S. Yusuf** (Canada) - **A. Zampelas** (Greece) - **A. Zanchetti** (Italy)

*Representatives from:*

*Regulatory Agencies, Government Health Organizations, Primary Care and other Stakeholders.*

## PARTICIPANTS

The Symposium will provide information on the state-of-the-art of global risk and on the most recent therapeutic advances to basic scientists, epidemiologists, cardiologists, endocrinologists, internists, geriatricians, and other health care professionals. Officers from regularly agencies will also benefit from the scientific, clinical and economic discussions held during the Symposium.

Special sessions will be dedicated to the General Practitioners.

## CME CREDITS (EACCME - ECM - EBAC - CME)

CME accreditation (Italian, European, USA, EBAC) will be applied for the entire meeting.

## SCIENTIFIC-ORGANIZING SECRETARIATS

Main Office - **MRF 2008**

**Fondazione Giovanni Lorenzini  
Medical Science Foundation**

Via A. Appiani 7 - 20121 Milan (Italy)

Phone: (+39) 02 29006267 - Fax: (+39) 02 29007018

Email: [mrf@lorenzinfoundation.org](mailto:mrf@lorenzinfoundation.org)

Branch Office - **MRF 2008**

**Giovanni Lorenzini Medical Foundation**

6535 Fannin, MS A-601 - Suite 754A

Houston, TX 77030 (USA)

Phone: (+1) 713 7970401 - Fax: (+1) 713 7968853

Email: [mrf@bcm.tmc.edu](mailto:mrf@bcm.tmc.edu)

[www.lorenzinfoundation.org](http://www.lorenzinfoundation.org)